SAN DIEGO, Dec. 15, 2015 /PRNewswire/ -- eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced that Alana McNulty has joined eFFECTOR as its full-time chief financial officer. Ms. McNulty has managed finance and operations at eFFECTOR on a consulting basis since 2012. Over her career she has led or played a key role in transactions with an aggregate value greater than $1.3 billion, including private and public financings, mergers and acquisitions, corporate partnerships and debt financings. Ms. McNulty most recently served on the management teams of Lumena Pharmaceuticals and Excaliard Pharmaceuticals, helping to guide and grow these companies until their respective acquisitions.
eFFECTOR Therapeutics logo
"Alana's demonstrated capabilities as an accomplished finance executive will be of great importance to eFFECTOR as we continue to advance our pipeline of selective translation regulators for cancer," said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. "Her appointment on a full-time basis is part of our ongoing plan to build an outstanding management team at eFFECTOR in order to realize the promise of translation regulation as a novel approach to therapy for cancer patients."
Prior to eFFECTOR, Ms. McNulty served as CFO at Lumena Pharmaceuticals, acquired by Shire in 2014, and Excaliard Pharmaceuticals, acquired by Pfizer in 2011. Previously, Ms. McNulty served in a similar capacity at BrainCells and Elitra Pharmaceuticals. Before those roles, she served as General Manager of the Advanced Tissue Sciences/Smith and Nephew JV, and previously led corporate partnership negotiations as Executive Director of Corporate Development for Advanced Tissue Sciences. She began her career as an Associate at Bear Stearns. Ms. McNulty received her B.A. in Biology at the University of California, Santa Barbara, and her M.B.A. at the University of California, Los Angeles.
"I am thrilled to join eFFECTOR at this exciting time for the company," said Ms. McNulty. "I look forward to working with Steve and the rest of management team to optimize our corporate strategy as we begin clinical development of the company's first product candidate."
About eFFECTOR Therapeutics
eFFECTOR Therapeutics is pioneering the discovery and development of translation regulators as a new class of small molecule therapeutics for cancer. The company's investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTOR's most advanced program focuses on the development of eFT508, a highly selective MNK1 and MNK2 inhibitor. MNK1 and 2 are kinases acting as signal integrators at the convergence of multiple oncogenic pathways to regulate production of disease-driving proteins. The company has additional translation regulation programs currently in discovery. eFFECTOR has raised $55M in Series A financing from top-tier private and corporate venture funds, including U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One and The Column Group. For more information visit www.effector.com
Heidi Chokeir, Ph.D.